Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
收藏官方服务：
资源简介：
Supplementary materials for the BE BRIGHT 4-Year Efficacy and Safety manuscript, including Plain Language Summary and supplementary methods, tables, and figures.
提供机构：
Mendeley Data创建时间：
2025-04-04
